Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.
The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.
Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.
The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.
LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings
3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies
3.4 Government regulations
3.4.1 Regulations in Middle East
3.5 Reimbursement scenario
3.5.1 Reimbursement in Middle East
3.6 Drivers
3.6.1 Rising incidence and prevalence of various cancer types
3.6.2 Growing importance of biological and targeted drug therapies
3.6.3 Increasing funding and aid from public and private sector
3.7 Restraints
3.7.1 High cost of drug development and threat of failure
3.7.2 Adverse effects of cancer drug therapy
3.8 Opportunities
3.8.1 Advancement of anti-cancer drugs research
3.8.2 Healthcare and medical awareness
CHAPTER 4 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-2021
4.1 Chemotherapy
4.1.1 Market size and forecast
4.2 Targeted therapy
4.2.1 Market size and forecast
4.3 Immunotherapy (biologics therapy)
4.3.1 Market size and forecast
4.4 Hormonal therapy
4.4.1 Market size and forecast
4.5 Others
4.5.1 Market size and forecast
CHAPTER 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-2021
5.1 Blood cancer
5.1.1 Market size and forecast
5.2 Breast cancer
5.2.1 Market size and forecast
5.3 Gastrointestinal cancer
5.3.1 Market size and forecast
5.4 Prostate cancer
5.4.1 Market size and forecast
5.5 Respiratory/lung cancer
5.5.1 Market size and forecast
5.6 Skin cancer
5.6.1 Market size and forecast
5.7 Other cancers
5.7.1 Trends in treatment of other cancer types
5.7.2 Market size and forecast
CHAPTER 6 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES,2014-2021
6.1 Brazil
6.1.1 Market size and forecast
6.2 Argentina
6.2.1 Market size and forecast
6.3 Nigeria
6.3.1 Market size and forecast
6.4 South Africa
6.4.1 Market size and forecast
6.5 Iraq
6.5.1 Market size and forecast
6.6 Iran
6.6.1 Market size and forecast
6.7 Algeria
6.7.1 Market size and forecast
6.8 Saudi Arabia
6.8.1 Market size and forecast
6.9 Egypt
6.9.1 Market size and forecast
6.10 Other LAMEA countries
6.10.1 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Company overview
7.1.2 Business performance
7.1.3 Operating business segment overview
7.1.4 Key strategies and development
7.1.5 SWOT analysis
7.2 AstraZeneca PLC.
7.2.1 Company overview
7.2.2 Business performance
7.2.3 Key strategies and development
7.2.4 SWOT analysis and strategic conclusions
7.3 Roche Diagnostics
7.3.1 Company overview
7.3.2 Operating business segment overview
7.3.3 Business performance
7.3.4 Key strategies moves and development
7.3.5 SWOT analysis
7.4 GlaxoSmithKline PLC
7.4.1 Company overview
7.4.2 Operating business segment overview
7.4.3 Business performance
7.4.4 Key strategies move and development
7.4.5 SWOT Analysis
7.5 Merck & Company
7.5.1 Company overview
7.5.2 Operating business segment overview
7.5.3 Business performance
7.5.4 Key strategies move and development
7.5.5 SWOT analysis
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Operating business segment overview
7.6.3 Business performance
7.6.4 Key strategies move and development
7.6.5 SWOT analysis
7.7 AbbVie Inc.
7.7.1 Company overview
7.7.2 Business performance
7.7.3 Strategic moves and developments
7.7.4 SWOT analysis
7.8 Sanofi
7.8.1 Company overview
7.8.2 Operating business segment overview
7.8.3 Business performance
7.8.4 Key strategies move and development
7.8.5 SWOT analysis
7.9 EIMC United Pharmaceuticals (EUP)
7.9.1 Company overview
7.9.2 Operating business segment overview
7.9.3 Key strategies move and development
7.9.4 SWOT analysis
7.10 Actavis plc
7.10.1 Company overview
7.10.2 Operating business segment overview
7.10.3 Business performance
7.10.4 Key strategies move and development
7.10.5 SWOT analysis
List of Figures
FIG. 1 TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)
FIG. 2 TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)
FIG. 3 TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)
FIG. 4 TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)
FIG. 5 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 11 LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)
FIG. 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
FIG. 13 LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014
FIG. 14 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
FIG. 15 LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014
FIG. 16 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
FIG. 17 LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014
FIG. 18 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
FIG. 19 LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014
FIG. 20 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
FIG. 21 LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014
FIG. 22 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
FIG. 23 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
FIG. 24 AMGEN INC. REVENUE BY GEOGRAPHY (2014)
FIG. 25 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)
FIG. 26 SWOT ANALYSIS OF AMGEN INC.
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)
FIG. 29 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 30 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)
FIG. 31 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 32 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2014)
FIG. 33 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 34 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 35 MERCK & CO. REVENUE BY GEOGRAPHY (2014)
FIG. 36 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY (2014)
FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 39 SWOT ANALYSIS OF NOVARTIS AG
FIG. 40 NET SALES REVENUES OF ABBVIE BY GEOGRAPHY, 2014 ($MILLION)
FIG. 41 SWOT ANALYSIS OF ABBVIE
FIG. 42 SANOFI REVENUE BY GEOGRAPHIES (2014)
FIG. 43 SANOFI REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 44 SWOT ANALYSIS OF SANOFI
FIG. 45 SWOT ANALYSIS OF EUP
FIG. 46 ACTAVIS CORPORATION REVENUE BY PRODUCT SALES (2014)
FIG. 47 SWOT ANALYSIS OF ACTAVIS PLC
List of Tables
TABLE 1 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 2 LAMEA ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (2012)
TABLE 3 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 4 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2014 2021 ($MILLION)
TABLE 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 11 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES, 2014 2021 ($MILLION)
TABLE 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
TABLE 13 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
TABLE 14 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
TABLE 15 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
TABLE 16 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
TABLE 17 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
TABLE 18 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
TABLE 19 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES, 2014 2021 ($MILLION)
TABLE 20 BRAZIL ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 21 ARGENTINA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 22 NIGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 23 SOUTH AFRICA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 24 IRAQ ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 25 IRAN ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 26 ALGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 27 SAUDI ARABIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 28 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 29 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 30 AMGEN INC. SNAPSHOT
TABLE 31 ASTRAZENECA SNAPSHOT
TABLE 32 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 33 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 34 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 36 MERCK & COMPANY SNAPSHOT
TABLE 37 MERCK & CO. OPERATING SEGEMENTS
TABLE 38 NOVARTIS AG SNAPSHOT
TABLE 39 NOVARTIS AG OPERATING SEGEMENTS
TABLE 40 ABBVIE INC. SNAPSHOT
TABLE 41 SANOFI SNAPSHOTS
TABLE 42 SANOFI OPERATING SEGEMENTS
TABLE 43 EIMC UNITED PHARMA SNAPSHOTS
TABLE 44 ACTAVIS CORPORATION SNAPSHOTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
